Previous case reports indicated that preoperative mTOR inhibitor therapy for TSC‐associated AML may lower the incidence of recurrence and the difficulty of partial nephrectomy (PN).10, 11. The gene discussed is MTOR; the disease is acute myeloid leukemia.